Agomab announces positive phase 2a interim results for AGMB-129 - PharmaTimes FSCD therapy meets all endpoints in interim analysis

#Agomab #AGMB129 #FSCDtherapy #AgomabTherapeutic #STENOVAclinicaltrial #gastrointestinalrestrictedsmallmoleculeinhibitor #ALK5 #fibrostenosingCrohnsdisease #FSCD #symptomaticFSCD #FSCDpatients #STENOVAstudy #FDAFastTrackDesignation #FDA
pharmatimes.com/news/agomab-...

#AGOMAB